J Neuroimmunol 2003 May;138(1-2):56-64
Jolivalt CG, Howard RB, Chen LS, Mizisin AP, Lai CS.
Medinox Inc., Suite 201, 11575 Sorrento Valley Road, 92121, San Diego, CA, USA
Immunotherapy improves experimental autoimmune encephalomyelitis (EAE), a model of multiple sclerosis (MS), while excessive production of nitric oxide (NO) has been implicated in the pathogenesis of this disease.
Here, we show that disease progression in SJL/J mice with EAE is improved after treatment with either a subtherapeutic dose of cyclosporine A (CsA) or NOX-100, a nitric oxide scavenger.
Importantly, the impact of subtherapeutic doses of CsA in combination with NOX-100 on disease progression in EAE was greater than that attained with either agent alone and led to near total protection.
CNS inflammation and gene expression of proinflammatory cytokines and iNOS were also significantly reduced after treatment.
These observations point to the potential therapeutic utility of NOX-100 as a dose-reducing agent for CsA in the treatment of MS.